SMAD4 loss have been correlated with tumor spread and worse prognosis, regardless of tumor size, grade and lymph node involvement [35,75], but we must consider that its loss is associated with the classical subtype; most basal subtypes retain SMAD4 expression, suggesting that alteration in other pathways may lead to the same outcome [16]. The gene discussed is SMAD4; the disease is neoplasm.